Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy
Go back to Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy| (NASDAQ: CRBU) | Delayed: 1.64 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.64 | 52 Week High | $ | |||
| Open | $1.64 | 52 Week Low | $ | |||
| Day High | $1.64 | P/E | N/A | |||
| Day Low | $1.64 | EPS | $ | |||
| Volume | 6,461 | |||||
